James Condulis
Stock Analyst at Stifel
(1.74)
# 2,979
Out of 5,149 analysts
11
Total ratings
37.5%
Success rate
5.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $21 | $14.11 | +48.83% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Hold | $24 → $6 | $4.90 | +22.45% | 2 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $30.41 | +64.45% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $3.33 | +200.30% | 1 | Dec 5, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $60.72 | +58.10% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $37.72 | +186.32% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $28.81 | +4.13% | 1 | Jan 22, 2025 |
Amylyx Pharmaceuticals
Mar 3, 2026
Initiates: Buy
Price Target: $21
Current: $14.11
Upside: +48.83%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Hold
Price Target: $24 → $6
Current: $4.90
Upside: +22.45%
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $30.41
Upside: +64.45%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $3.33
Upside: +200.30%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $60.72
Upside: +58.10%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $37.72
Upside: +186.32%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $28.81
Upside: +4.13%